EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety

Brendan Saloner iD, Penn Whitley, Eric Dawson, Steven Passik, Adam J Gordon, Bradley D Stein

Addiction · 2023

DOI: 10.1111/add.16180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction, 2023. Verfasst von Brendan Saloner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Cocaine, Methamphetamine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, Institute of Development and Economic Alternatives.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients in methadone medication treatment for opioid use disorder (M‐MOUD) typically have a complex history of opioid use, often in combination with other drugs. It is unknown how frequently M‐MOUD patients experience persistent substance or polysubstance use. We measured trends in illicit substance use in a large, multistate population of M‐MOUD patients and persistence of substance use in the first year of treatment.

Design

Retrospective cohort study of United States (US) M‐MOUD patients from 2017 to 2021, focused on urine drug specimens provided for testing to Millennium Health, a third‐party laboratory. Specimens were analyzed using liquid chromatography–tandem mass spectrometry (LC‐MS/MS). Generalized estimating equations (GEE) were used to estimate the average trends in positivity during time in treatment.

Setting

Specimens were obtained from clinics in 10 US states that provided at least 300 unique patients during the study period (Alaska, Arizona, Florida, Illinois, Kentucky, Minnesota, New Mexico, Ohio, Virginia and Washington).

Participants

Patients with opioid use disorder receiving M‐MOUD ( n = 16 386).

Measurements

Positivity rates for heroin, fentanyl, methamphetamine and cocaine.

Findings

From 2017 to 2021, yearly crude positivity rates for first collected specimens increased for fentanyl (13.1%–53.0%, P < 0.001), methamphetamine (10.6%–27.2%, P < 0.001) and cocaine (13.8%–19.5%, P < 0.001); for heroin positivity did not significantly change (6.9%–6.5%, P = 0.74). In regression models estimating patient trajectories from week 1 to week 52, marginal fentanyl positivity declined from 21.8% to 17.1% (incidence rate ratio [IRR] = 0.78, P < 0.001) and heroin positivity declined from 8.4% to 4.3% (IRR = 0.51, P < 0.001), but positivity for methamphetamine and cocaine did not significantly change, remaining at an average of 17.7% (IRR = 0.98, P = 0.53) and 9.2% (IRR = 0.96, P = 0.36), respectively.

Conclusions

Between 2017 and 2021, United States patients presenting to opioid treatment programs increasingly tested positive for fentanyl, methamphetamine and cocaine. Methadone medication treatment for opioid use disorder appears to remain an effective intervention for reducing illicit opioid use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersCocaineMethamphetamineHumansUnited StatesMethadoneAnalgesics, OpioidHeroinRetrospective StudiesChromatography, LiquidPatient SafetyTandem Mass SpectrometryFentanyl

Stichwörter der Autor:innen

Methadone maintenancecocainefentanylopioid use disorderpolysubstance useurine drug testing

Substanzen

MethadoneAnalgesics, OpioidHeroinFentanylCocaineMethamphetamine

Autor:innen und Institutionen

  • Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Millennium Health, San Diego, California, USA.
  • University of Utah and Veterans Health Administration, Salt Lake City, Utah, USA.
  • RAND Corporation, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Brendan Saloner

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse
  • Institute of Development and Economic Alternatives

Zitieren

APA

Saloner, B., Whitley, P., Dawson, E., Passik, S., Gordon, A. J., & Stein, B. D. (2023). Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. Addiction. https://doi.org/10.1111/add.16180

Vancouver

Saloner B, Whitley P, Dawson E, Passik S, Gordon AJ, Stein BD. Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. Addiction. 2023. doi:10.1111/add.16180

BibTeX
@article{Saloner2023,
  author = {Saloner, Brendan and Whitley, Penn and Dawson, Eric and Passik, Steven and Gordon, Adam J and Stein, Bradley D},
  title = {Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety},
  journal = {Addiction},
  year = {2023},
  doi = {10.1111/add.16180}
}
Kostenlos starten →